Home > Cardiology > Novel oral anticoagulant asundexian shows promise in phase 2 testing

Novel oral anticoagulant asundexian shows promise in phase 2 testing


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet
Reuters Health - 13/04/2022 - For patients with atrial fibrillation (AF), an investigational oral inhibitor of activated coagulation factor XI (FXIa) may protect against thromboembolic events with less risk of bleeding than currently available direct oral anticoagulants (DOACs) that mainly inhibit factor X, early testing suggests. Asundexian is being developed by Bayer, which funded the phase 2 PACIFIC-AF study, with the results reported at the American College of Cardiology 2022 Scientific Sessions and simultaneously published in The Lancet. The trial tested asundexian 20 mg or 50 mg once daily against apixiban 5 mg twice daily in 753 patients (mean age, 73.7 years, 41% women) with AF, a CHA2DS2-VASc score of at least 2 in men or at least 3 in women, and increased bleeding risk. Both once-daily doses of asundexian were well tolerated and led to "reliable" and "near-complete" suppression of FXIa, with significantly lower rates of bleeding compared with apixab...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on